

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7625174

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HAZEL HUNT	05/03/2021
RECEIVING PARTY DATA	
Name:	CORCEPT THERAPEUTICS INCORPORATED
Street Address:	149 COMMONWEALTH DRIVE
City:	MENLO PARK
State/Country:	CALIFORNIA
Postal Code:	94025
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15734525
CORRESPONDENCE DATA	
Fax Number:	(415)432-6001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	4154326000
Email:	TMIIngrande@mintz.com
Correspondent Name:	ALEXANDER R. TRIMBLE
Address Line 1:	MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO, P.C.
Address Line 2:	ONE FINANCIAL CENTER
Address Line 4:	BOSTON, MASSACHUSETTS 02111
ATTORNEY DOCKET NUMBER:	052691-503N01US
NAME OF SUBMITTER:	ALEXANDER R. TRIMBLE
SIGNATURE:	/ALEXANDER R. TRIMBLE/
DATE SIGNED:	11/02/2022
Total Attachments: 2	
source=052691-503N01US_-503001WO_Assignment_H. Hunt to Corcept#page1.tif	
source=052691-503N01US_-503001WO_Assignment_H. Hunt to Corcept#page2.tif	

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) patent application titled

“PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS”;

U.S. Application Serial No. 15/734,525, filed December 2, 2020; and

International Application No. PCT/US2019/035229, filed June 3, 2019.

For good and valuable consideration, the receipt and sufficiency of which I acknowledge, I:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to **Corcept Therapeutics Incorporated**, a corporation of the State of Delaware, having a principal place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application, and any legal equivalent thereof in a foreign country or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) any legal equivalent thereof in a foreign country that are granted or issued upon, or that claim priority to, and all applications described in (b) of this paragraph or that disclose or

ASSIGNMENT

U.S. Serial No. 15/734,525 / PCT/US2019/035229

Attorney Docket No. 052691-503N01US

Page 2 of 2

claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

IN TESTIMONY WHEREOF, Assignor has signed her name on the date indicated:

Dated: 3 Nov 2021

H. J. Hunt
Hazel HUNT

DEED OF ACCEPTANCE

I (we), Corcept Therapeutics Incorporated, with offices at 149 Commonwealth Drive, Menlo Park, CA 94025, USA declare that I (we) accept the rights given in the attached Assignment.

BY:

JK Belanoff MD 5/03/21

Name: Joseph K. Belanoff, MD
Title: Chief Executive Officer